

## Screening

### UCI 16-77

Identification of Features Associated with Dysplasia Using the NvisionVLE Imaging System Pilot Trial (Chang)

### UCI 16-99

Multi-center Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients with Previously-Untreated Dysplastic Barrett's Esophagus (Chang)

## Correlative

### UCI 16-88

Development of Esophageal and Gastric Cancer Patient Derived Xenograft Mouse Models to Investigate Chemotherapy Resistance and Tumor Cell Response (Lyou)

### UCI 14-36

A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay (Seery)

### UCI 14-25

Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

### UCI 16-31

Importin  $\alpha$  is a Novel Biomarker of Barrett's Esophagus (BE)-Related Dysplasia & Cancer and Promotes Growth of BE-Derived Cancer Cells by Inducing Aberrant VEGF Expression (Samarasena)

## Stage IV/Advanced

### ECOG-EAY131

Molecular Analysis for Therapy Choice (MATCH) (Seery)

### UCI 16-96

A Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

### UCI 17-50\*\*

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor (Ou)

**GASTRO-  
ESOPHAGEAL  
CANCER**